Iovance Biotherapeutics(IOVA) - 2024 Q4 - Annual Results

Exhibit 99.1 Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024 Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and$164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaf irming FY25 Total Product Revenue Guidance of $450M-$475M FY25 Cash Burn Anticipated to be Under $300M 2025 Regulatory Approvals for Amtagvi Expected in the UK, EU, and Canada Enrollment Accelerating Acros ...